Paola A. Gehrig, MD 
Associate Professor of Obstetrics & Gynecology.
Division of Gynecologic Oncology. 
 
Phone: (919) 966-1194
Fax: (919) 966-2646
E-Mail: paola_gehrig@med.unc.edu
Mailing Address: CB#7570, UNC-Chapel Hill
Chapel Hill, NC 27599-7570

Education
Doctor of Medicine: University of Florida College of Medicine 1989-1993

Residency
University of Virginia, 1993-1997

Fellowship
University of North Carolina 1997 - 2000

Board Certification
2003
Diplomate
Specialty, Gynecologic Oncology
American Board of Obstetrics and Gynecology

2001
Diplomate
Obstetrics and Gynecology
American Board of Obstetrics and Gynecology

1997
American College of Obstetrics and Gynecology

1993
National Board of Medical Examiners

Honors & Awards
2005
Golden Tarheel Teaching Award
University of North Carolina at Chapel Hill
 
2003
American Professors of Gynecology & Obstetrics
Excellence in Teaching Award
University of North Carolina at Chapel Hill

2002
Best fellow presentation award
Annual Meeting of the Mid-Atlantic
Gynecologic Oncology Society
Richmond, VA

2000
Second place award for poster presentation
District IV ACOG Meeting
Asheville, NC

Societies and Memberships
• American College of Obstetrics and Gynecology
- - Junior Fellow, 1997.
• American Association for Cancer Research,
- - Associate Member

Recent Publications
Bae-Jump V, Zhou C, Gehrig PA, Whang Y, Boggess JF. The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels. Gynecologic Oncology 101:305-10, 2006.

Sutton G, Axelrod JH, Bundy BN, Roy T, Homesley H, Lee RB, Gehrig PA, Zaino R. Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium. A phase II study of the Gynecologic Oncology Group. Gynecologic Oncology 100:349-54.

Bae-Jump V, Zhou C, Gehrig PA, Whang YE, Boggess JF. Rapamycin inhibits hTERT telomerase mRNA expression independent of cell cycle arrest. Gynecologic Oncology 100:487-94, 2006.

Dietrich CS 3rd, Modessit SC, Depriest PD, Ueland FR, Wilder J, Reedy MB, Pavlik EJ, Kryscio R, Cibull M, Giesler J, Manahan K, Huh W, Cohn D, Powell M, Slomovitz B, Higgins RV, Merritt W, Hunter J, Puls L, Gehrig PA, van Nagell JR Jr. The efficacy of adjuvant platinum-based chemotherapy in stage I uterine papillary serous carcinoma. Gynecologic Oncology 99:557-63, 2005.

SantaCruz MR, Proctor L, Thomas DB, Gehrig PA. Extraskeletal myxoid chondrosarcoma: A report of a gynecologic case. Gynecologic Oncology 98:498-501.

Rao GG, Skinner EN, Gehrig PA, Duska LR, Schorge JO. Fertility-sparing surgery for ovarian low malignant potential tumors. Gynecologic Oncology 98:263-266, 2005.

Skinner E, Boruta DM, Gehrig PA, Boggess JF, Fowler WC, Van Le L. Consolidation therapy with weekly paclitaxel infusion in ovarian cancer: An extended follow-up. Gynecologic Oncology 98:59-62, 2005.

Gehrig PA.  Uterine Serous Carcinoma: An Update, Accepted 2005, Women’s Oncology Review.

Bae-Jump V, Zhou C, Gehrig PA, Whang Y, Boggess JF.  The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels.  Accepted 2005, Gynecologic Oncology

Bae-Jump V, Zhou C, Gehrig PA, Whang YE, Boggess JF.  Rapamycin inhibits hTERT telomerase mRNA expression independent of cell cycle arrest.  Accepted 2005, Gynecologic Oncology.

SantaCruz MR, Proctor L, Thomas DB, Gehrig PA.  Extraskeletal myxoid chondrosarcoma: A report of a gynecologic case.  Accepted 2005, Gynecologic Oncology.

Rao GG, Skinner EN, Gehrig PA, Duska LR, Schorge JO.  Fertility-sparing surgery for ovarian low malignant potential tumors.  Gynecologic Oncology 98:263-266, 2005.

Skinner E, Boruta DM, Gehrig PA, Boggess JF, Fowler WC, Van Le L. Consolidation therapy with weekly paclitaxel infusion in ovarian cancer: An extended follow-up. Accepted 2005, Gynecologic Oncology.

Gehrig PA, Bae-Jump V, Boggess JF, Groben PA, Fowler WC, Van Le L. Association between uterine serous carcinoma and breast cancer. Gynecologic Oncology, 2004, 94: 208-211.

Boruta DM, Gehrig PA, Boggess JF, Groben PA, Bae-Jump V, , Fower Jr WC, Van Le L. Uterine serous and grade 3 endometrioid carcinomas: Is there a survival difference? Cancer, 2004, 101: 2214-21.

Gehrig PA, Bae-Jump VL, , Boggess JF, Groben PA, Fowler Jr WC, Van Le L. Association between uterine serous carcinoma and breast cancer. Gynecologic Oncology, 2004, 94:208-211.

Boruta DM, Fowler WC, Gehrig PA, Boggess JF, Walton LA, Van Le L. Weekly paclitaxel infusion as salvage therapy in ovarian cancer. Cancer Investigation, 2003, 21:675-81.

Bourgeois J, Mullin P, Veljovich D. Ob/Gyn Recall. Williams and Wilkins. 1997
 
Mullin P, Pelkey T, Stoler, Underwood PB, Taylor PT, Anderson WA, Rice LW: Mlignant mixed mesodermal tumors an dendometrial adenocarcinoma, a comparison. Submitted Gynecol Oncol.

Gehrig PA, Geradts J., Van Le L:  Comparitiv study of estrogen and progesterone receptors by radioimunoassay an d immunohistochemistry. Manuscript in preparation.

Gehrig PA, Watson JM, Li P, Fowler WC, Haskill JS: Taxol mediated apoptosisi may involve other pathways other than microtubule stabilization. Manuscript in preparation.

Special Interests
Mechanisms of chemotherapeutic agents
Chemotherapy Trials

Research Focus
The focus of Dr. Gehrig's research has been mechanisms of resistance to Taxol in ovarian cancer, both on a cellular and molecular level.